BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

861 related articles for article (PubMed ID: 29720976)

  • 1. Carbonate Apatite Nanoparticles Act as Potent Vaccine Adjuvant Delivery Vehicles by Enhancing Cytokine Production Induced by Encapsulated Cytosine-Phosphate-Guanine Oligodeoxynucleotides.
    Takahashi H; Misato K; Aoshi T; Yamamoto Y; Kubota Y; Wu X; Kuroda E; Ishii KJ; Yamamoto H; Yoshioka Y
    Front Immunol; 2018; 9():783. PubMed ID: 29720976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipid Nanoparticles Potentiate CpG-Oligodeoxynucleotide-Based Vaccine for Influenza Virus.
    Shirai S; Shibuya M; Kawai A; Tamiya S; Munakata L; Omata D; Suzuki R; Aoshi T; Yoshioka Y
    Front Immunol; 2019; 10():3018. PubMed ID: 31998305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunostimulatory Properties of Lipid Modified CpG Oligonucleotides.
    Yu C; An M; Li M; Liu H
    Mol Pharm; 2017 Aug; 14(8):2815-2823. PubMed ID: 28686452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-Modified CpG Oligodeoxynucleotide Forming Guanine-Quadruplex Structure Complexes with ε-Poly-
    Zhao D; Tu ATT; Shobo M; Le NBT; Yoshikawa C; Sugai K; Hakamata Y; Yamazaki T
    Biomolecules; 2022 Dec; 12(12):. PubMed ID: 36551297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Three CpG oligodeoxynucleotide classes differentially enhance antigen-specific humoral and cellular immune responses in mice.
    Liu Y; Luo X; Yang C; Yu S; Xu H
    Vaccine; 2011 Aug; 29(34):5778-84. PubMed ID: 21664398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Double-stranded phosphodiester cytosine-guanine oligodeoxynucleotide complexed with calcium phosphate as a potent vaccine adjuvant for activating cellular and Th1-type humoral immunities.
    Hanagata N; Li X; Chen MH; Li J; Hattori S
    Int J Nanomedicine; 2018; 13():43-62. PubMed ID: 29317815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Attachment of class B CpG ODN onto DOTAP/DC-chol liposome in nasal vaccine formulations augments antigen-specific immune responses in mice.
    Tada R; Muto S; Iwata T; Hidaka A; Kiyono H; Kunisawa J; Aramaki Y
    BMC Res Notes; 2017 Jan; 10(1):68. PubMed ID: 28126014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of a balanced Th1/Th2 immune responses by co-delivery of PLGA/ovalbumin nanospheres and CpG ODNs/PEI-SWCNT nanoparticles as TLR9 agonist in BALB/c mice.
    Ebrahimian M; Hashemi M; Maleki M; Abnous K; Hashemitabar G; Ramezani M; Haghparast A
    Int J Pharm; 2016 Dec; 515(1-2):708-720. PubMed ID: 27989827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of Immune Responses to an Inactivated Avian Influenza Virus Vaccine Adjuvanted with Nanoparticles Containing CpG ODN.
    Singh SM; Alkie TN; Abdelaziz KT; Hodgins DC; Novy A; Nagy É; Sharif S
    Viral Immunol; 2016 Jun; 29(5):269-75. PubMed ID: 27077969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytosine-phosphate-guanine oligodeoxynucleotides containing GACGTT motifs enhance the immune responses elicited by keyhole limpet hemocyanin antigen in dairy cattle.
    Chu CY; Lee SC; Liu SS; Lin YM; Shen PC; Yu C; Lee KH; Zhao X; Lee JW
    Nucleic Acid Ther; 2011 Oct; 21(5):323-32. PubMed ID: 21916610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delivery of an inactivated avian influenza virus vaccine adjuvanted with poly(D,L-lactic-co-glycolic acid) encapsulated CpG ODN induces protective immune responses in chickens.
    Singh SM; Alkie TN; Nagy É; Kulkarni RR; Hodgins DC; Sharif S
    Vaccine; 2016 Sep; 34(40):4807-13. PubMed ID: 27543454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-dependent immunostimulatory effect of CpG oligodeoxynucleotides and their delivery system.
    Hanagata N
    Int J Nanomedicine; 2012; 7():2181-95. PubMed ID: 22619554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. pH-Responsive nanoparticle vaccines for dual-delivery of antigens and immunostimulatory oligonucleotides.
    Wilson JT; Keller S; Manganiello MJ; Cheng C; Lee CC; Opara C; Convertine A; Stayton PS
    ACS Nano; 2013 May; 7(5):3912-25. PubMed ID: 23590591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CpG ODNs treatments of HIV-1 infected patients may cause the decline of transmission in high risk populations - a review, hypothesis and implications.
    Becker Y
    Virus Genes; 2005 Mar; 30(2):251-66. PubMed ID: 15744581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An indispensable role of type-1 IFNs for inducing CTL-mediated complete eradication of established tumor tissue by CpG-liposome co-encapsulated with model tumor antigen.
    Wakita D; Chamoto K; Zhang Y; Narita Y; Noguchi D; Ohnishi H; Iguchi T; Sakai T; Ikeda H; Nishimura T
    Int Immunol; 2006 Mar; 18(3):425-34. PubMed ID: 16415100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple effects of immunostimulatory DNA on T cells and the role of type I interferons.
    Sun S; Zhang X; Tough D; Sprent J
    Springer Semin Immunopathol; 2000; 22(1-2):77-84. PubMed ID: 10944802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose sparing of CpG oligodeoxynucleotide vaccine adjuvants by nanoparticle delivery.
    Diwan M; Elamanchili P; Cao M; Samuel J
    Curr Drug Deliv; 2004 Oct; 1(4):405-12. PubMed ID: 16305402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunization with antigenic peptides complexed with β-glucan induces potent cytotoxic T-lymphocyte activity in combination with CpG-ODNs.
    Mochizuki S; Morishita H; Kobiyama K; Aoshi T; Ishii KJ; Sakurai K
    J Control Release; 2015 Dec; 220(Pt A):495-502. PubMed ID: 26562685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic effect of dual targeting vaccine adjuvant with aminated β-glucan and CpG-oligodeoxynucleotides for both humoral and cellular immune responses.
    Jin JW; Tang SQ; Rong MZ; Zhang MQ
    Acta Biomater; 2018 Sep; 78():211-223. PubMed ID: 30098441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanoparticles encapsulating hepatitis B virus cytosine-phosphate-guanosine induce therapeutic immunity against HBV infection.
    Lv S; Wang J; Dou S; Yang X; Ni X; Sun R; Tian Z; Wei H
    Hepatology; 2014 Feb; 59(2):385-94. PubMed ID: 23907803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.